StockNews.AI
VVUS
StockNews.AI
153 days

VIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. Drew

1. VIVUS to feature on Health Uncensored discussing QSYMIA's benefits. 2. QSYMIA is a leading weight-management medication in the U.S. 3. Obesity rates are projected to reach one billion by 2030. 4. VIVUS emphasizes its commitment to addressing obesity through QSYMIA. 5. The episode aims to raise awareness of weight management solutions.

11m saved
Insight
Article

FAQ

Why Bullish?

Increased visibility from media exposure can lead to higher sales and interest in QSYMIA. Historical data shows that media appearances often boost stock prices in biopharma sectors, as seen with other companies post-coverage.

How important is it?

The focus on QSYMIA and significant obesity issues aligns well with VIVUS's market positioning, indicating an opportunity for growth. This media appearance could lead to increased prescriptions and higher revenue.

Why Short Term?

Immediate increase in public awareness can drive short-term sales boosts. Marketing and awareness efforts typically result in faster market responses.

Related Companies

AMGNSYNPFEJNJNDA
March 19, 2025 06:30 ET  | Source: VIVUS LLC — Segment to air on Lifetime on Wednesday, March 19, at 7:30 AM ET/PT CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced an exclusive episode on Health Uncensored with Dr. Drew. The episode will feature John Amos, Chief Executive Officer at VIVUS LLC, along with leading weight-loss experts, to discuss QSYMIA® (phentermine and topiramate extended-release capsules CIV), the leading once-daily oral branded, weight-management medication. It is scheduled to air on Lifetime on Wednesday, March 19 at 7:30 AM ET/PT and can also be viewed on Health Uncensored’s website here. John Amos, Dr. Farhad Zangeneh, Medical Director of Endocrine, Diabetes and Osteoporosis Clinic, Dr. Dina Peralta-Reich, New York Weight Wellness Medicine Founder and Director, and Peter Maher, a QSYMIA patient, will join Dr. Drew Pinsky, host of Health Uncensored, to discuss weight management and the role QSYMIA can play in maintaining a healthy weight and lifestyle. “Obesity is a major health crisis, contributing to leading causes of death such as heart disease, stroke, and diabetes. With global obesity rates expected to reach one billion by 2030, the need for effective, science-driven solutions has never been more urgent. At VIVUS, and with QSYMIA, we are committed to providing a proven, safe and convenient once-daily oral medication to patients. Our mission is to not only address the complexities of obesity but to drive meaningful change in how it is managed, ensuring better outcomes for millions worldwide,” shared Mr. Amos. QSYMIA is the leading non-injectable branded weight loss medication in the U.S. for adults. QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight in some adults and certain pediatric patients aged 12 years and older. Health Uncensored with Dr. Drew is an innovative, informative and entertaining television series. Dr. Drew Pinsky introduces us to the most important ideas in the new era of health and medicine. From the latest medical breakthroughs to simple home health solutions, Dr. Drew discusses it all with leading experts. Health Uncensored with Dr. Drew topics are timely and compelling, including brain health, emotional resilience, vitality and aging, super foods for cancer prevention, and the “magic pill” of exercise. The program also informs us about the role each of us play in creating a healthier life and world. Dr. Drew brings his insight and knowledge to each episode as he presents a truly global picture of health practices, both new and time-tested. To learn more about Health Uncensored with Dr. Drew, visit https://drdrew.com/health-uncensored-with-dr-drew/. Check your local provider for TV channel listings for Lifetime. About VIVUSVIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit http://www.vivus.com. About QSYMIAQSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. For more information on QSYMIA, please visit https://QSYMIA.com/ Important Safety Information for QSYMIADo not take QSYMIA if you are pregnant, planning to become pregnant, or become pregnant during QSYMIA treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in QSYMIA. QSYMIA can cause serious side effects, including birth defects (cleft lip/cleft palate), serious eye problems (secondary angle closure glaucoma), visual field defects (independent of elevated intraocular pressure), suicidal thoughts or actions, and severe rash with blisters and peeling skin. QSYMIA may slow the increase in height in children 12 years and older. Common side effects of QSYMIA in adults include numbness or tingling in the hands, arms, feet, or face (paraesthesia), dizziness, changes in the way foods taste or loss of taste (dysgeusia), trouble sleeping (insomnia), constipation, and dry mouth. Common side effects of QSYMIA in children aged 12 years and older include depression, dizziness, joint pain, fever, flu, and ankle sprain. For more information, please read the QSYMIA Medication Guide, Full Prescribing Information, and Risk of Birth Defects with QSYMIA patient brochure. Forward-Looking Statements Important Information and Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the “Bespeaks Caution” doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management’s beliefs and certain assumptions made by the Company’s management. These statements may be identified by the use of forward-looking words such as “will,” “shall,” “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “should,” “plan,” “likely,” “opportunity,” “estimated,” and “potential,” and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on our current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law. Forward-looking information about QSYMIA, including its potential benefits, approvals in potential markets outside the U.S. and anticipated product availability, involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any other markets or approved, whether QSYMIA will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSYMIA; uncertainties regarding the impact of COVID-19 on our business, operations, and financial results; and competitive developments. The above factors, risks and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results and may be beyond the Company’s control. New factors, risks and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company’s objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions or otherwise, unless otherwise required by law. Contacts VIVUS LLCT: +1 (650) 934-5200 Media – FINN Partners Glenn Silver glenn.silver@finnpartners.com T: +1 973-818-8198

Related News